Cogent Biosciences, Inc.

NASDAQ:COGT

Biotechnology

Healthcare
$27.74 +2.60%

+$0.88 today

Market cap
$4.83B
Beta
0.35
P/E (TTM)
-6.6
EPS (TTM)
-$5.26
52W Low $6.92High $43.73

Volume 1.68M

Average 2.15M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$264.44M

FY 2025 · Annual

Investing Cash Flow

-$399.53M

FY 2025 · Annual

Financing Cash Flow

$878.23M

FY 2025 · Annual

+309.5% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(72.27M)(140.24M)(192.41M)(255.86M)(328.94M)
Depreciation & Amortization147K5.88M3.59M4.35M4.58M
Deferred Income Tax00000
Stock-Based Compensation11.69M18.37M30.62M39.74M46.08M
Change in Working Capital2.02M751K11.44M11.6M8.01M
Accounts Receivables00000
Inventory00000
Accounts Payables2.75M2.36M4.81M1.36M(2.51M)
Other Working Capital(731K)(1.61M)6.63M10.24M10.52M
Other Non-Cash Items(343K)(3.39M)(6.87M)(7.62M)5.82M
Operating Cash Flow(58.76M)(118.64M)(153.62M)(207.79M)(264.44M)
Capital Expenditures(1.72M)(6.86M)(2.8M)(573K)(1.55M)
Acquisitions (Net)0117.86K000
Purchases of Investments0(177.86M)(348.8M)(255.6M)(687.17M)
Sales of Investments060M253.78M294.45M289.2M
Other Investing Activities0(117.86K)000
Investing Cash Flow(1.72M)(124.72M)(97.82M)38.28M(399.53M)
Debt Repayment0000215.13M
Common Stock Issued38.01M161.95M161.82M213.34M712M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(30K)1.61M01.12M(48.9M)
Financing Cash Flow37.98M163.56M163.54M214.45M878.23M
Effect of Forex Changes00000
Net Change in Cash(22.51M)(79.8M)(87.91M)44.94M214.26M
Free Cash Flow(60.48M)(125.5M)(156.42M)(208.36M)(266M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$328.9M
+ D&A$4.6M
+ Stock-Based Comp$46.1M
+ Deferred Tax$0
+ Working Capital$8.0M
+ Other Non-Cash$5.8M
= Operating Cash Flow-$264.4M
- Capex-$1.6M
= Free Cash Flow-$266.0M

Analysis

FY2025 free cash flow is -$266.0M. FCF conversion is 80.9% of net income. Operating cash flow was -$264.4M, with capex of -$1.6M. The largest bridge item is Stock-Based Comp at $46.1M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 5, 2026
10-QQuarterly reportNov 5, 2026
4Statement of changes in beneficial ownershipOct 5, 2026
8-KCurrent reportSep 2, 2026
4Statement of changes in beneficial ownershipAug 31, 2026

Does COGT generate free cash flow?

Cogent Biosciences, Inc. (COGT) generated -$266.00M of free cash flow in fiscal 2025.

How much operating cash flow does COGT produce?

Operating cash flow was -$264.44M, before capital expenditures of $1.55M.